219 related articles for article (PubMed ID: 28248716)
1. Intraepithelial Melanoma in the Stomach After Treatment With Immune Checkpoint Blockade Therapy.
Shustef E; Torres-Cabala CA; Curry JL; Tetzlaff MT; Nagarajan P; Ivan D; Prieto VG; Aung PP
Am J Dermatopathol; 2017 Aug; 39(8):e116-e118. PubMed ID: 28248716
[TBL] [Abstract][Full Text] [Related]
2. Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis.
Bello E; Cohen JV; Mino-Kenudson M; Dougan M
J Immunother Cancer; 2019 Feb; 7(1):41. PubMed ID: 30744698
[TBL] [Abstract][Full Text] [Related]
3. Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab.
Moreira RB; Hamieh L; Gjini E; Lako A; Krajewski KM; Yoon CH; Ott PA
J Immunother Cancer; 2017 Jul; 5(1):61. PubMed ID: 28716097
[TBL] [Abstract][Full Text] [Related]
4. Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.
Gambichler T; Strutzmann S; Tannapfel A; Susok L
BMC Cancer; 2017 May; 17(1):327. PubMed ID: 28499411
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
Hwang SJ; Carlos G; Wakade D; Sharma R; Fernandez-Penas P
Melanoma Res; 2016 Aug; 26(4):417-20. PubMed ID: 27031538
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
7. The future of melanoma therapy: developing new drugs and improving the use of old ones.
Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V
Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206
[No Abstract] [Full Text] [Related]
8. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
9. The best treatments to use after checkpoint inhibition in melanoma.
McArthur G
Clin Adv Hematol Oncol; 2017 Apr; 15(4):242-245. PubMed ID: 28591097
[No Abstract] [Full Text] [Related]
10. Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus.
Maeda T; Yanagi T; Imafuku K; Kitamura S; Hata H; Izumi K; Ujiie H; Iwata H; Shimizu H
Int J Dermatol; 2017 Dec; 56(12):1477-1479. PubMed ID: 28762466
[No Abstract] [Full Text] [Related]
11. Metastatic malignant melanoma of the gastrointestinal tract.
Liang KV; Sanderson SO; Nowakowski GS; Arora AS
Mayo Clin Proc; 2006 Apr; 81(4):511-6. PubMed ID: 16610571
[TBL] [Abstract][Full Text] [Related]
12. Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports.
Schliep S; Agaimy A; Cavallaro A; Kiesewetter F; Schuler G; Heinzerling L
J Immunother Cancer; 2018 Jan; 6(1):2. PubMed ID: 29332608
[TBL] [Abstract][Full Text] [Related]
13. A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.
Wolner ZJ; Marghoob AA; Pulitzer MP; Postow MA; Marchetti MA
Br J Dermatol; 2018 Jan; 178(1):265-269. PubMed ID: 28132411
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy.
Plaquevent M; Greliak A; Pinard C; Duval-Modeste AB; Joly P
Melanoma Res; 2019 Jun; 29(3):311-312. PubMed ID: 31026247
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab prolongs survival in advanced melanoma.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
[No Abstract] [Full Text] [Related]
16. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
Di Giacomo AM; Margolin K
Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
[TBL] [Abstract][Full Text] [Related]
17. Novel therapies for unresectable and metastatic melanoma.
Karimkhani C; Reddy BY; Dellavalle RP; Sundararajan S
BMJ; 2017 Nov; 359():j5174. PubMed ID: 29191943
[No Abstract] [Full Text] [Related]
18. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
19. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
[TBL] [Abstract][Full Text] [Related]
20. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.
Failing JJ; Finnes HD; Kottschade LA; Allred JB; Markovic SN
Melanoma Res; 2016 Dec; 26(6):609-615. PubMed ID: 27603551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
